1H-3-Benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-, hydrochloride (1:1), (5R)- | 182486-38-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 1H-3-Benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-, hydrochloride (1:1), (5R)-
• 英文别名: 8-chloro-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol;hydrochloride
• CAS: 182486-38-0
• 化学式: C17H19Cl2NO
• 分子量: 324.2
• InChiKey: OYCAEWMSOPMASE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.09
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  23.5
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of parkinson's disease
  申请人：Knopp Neurosciences, Inc.

  公开号：EP2465500A1

  公开（公告）日：2012-06-20

  Therapeutically effective amounts of R(+) pramipexole and S(-) pramipexole for use in the treatment of Parkinson's disease or the symptoms thereof are provided.

  提供了用于治疗帕金森病或其症状的治疗有效量的R(+)普拉克索和S(-)普拉克索。
• Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of Parkinson's disease and their pharmaceutical compositions
  申请人：Knopp Neurosciences, Inc.

  公开号：EP2497472A1

  公开（公告）日：2012-09-12

  Pharmaceutical compositions comprising therapeutically effective amounts of R(+) and S(-) pramipexole, multicomponent pharmaceutical compositions of the same, and therapeutically effective amounts of R (+) and S(-) pramipexole for use in the treatment or prevention of Parkinson's disease or the symptoms thereof are provided.

  本发明提供了包含治疗有效量的 R(+) 和 S(-) 普拉克索的药物组合物、其多组分药物组合物，以及治疗有效量的 R(+) 和 S(-) 普拉克索，用于治疗或预防帕金森病或其症状。
• Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of Parkinson's disease and pharmaceutical compositions thereof
  申请人：Knopp Neurosciences, Inc.

  公开号：EP2497473A1

  公开（公告）日：2012-09-12

  There is provided a pharmaceutical composition comprising a therapeutically effective amount of R(+) pramipexole and a therapeutically effective amount of S(-) pramipexole, wherein said therapeutically effective amount of R(+) pramipexole is 50 milligrams plus or minus 10% to 5,000 milligrams plus or minus 10% and wherein said therapeutically effective amount of S(-) pramipexole is 0.125 milligrams plus or minus 10% to 4.5 milligrams plus or minus 10%, and therapeutically effective amounts of R (+) and S(-) pramipexole for use in the treatment or prevention of Parkinson's disease or the symptoms thereof.

  提供了一种药物组合物，其包含治疗有效量的R(+)普拉克索和治疗有效量的S(-)普拉克索，其中所述治疗有效量的R(+)普拉克索为50毫克正负10%至5000毫克正负10%，所述治疗有效量的S(-)普拉克索为0.125毫克正负10%至4.5毫克正负10%，治疗有效量的R(+)和S(-)普拉克索用于治疗或预防帕金森病或其症状。
• Methods and systems for drug screening and computational modeling
  申请人：Siekmeier Peter

  公开号：US20060089824A1

  公开（公告）日：2006-04-27

  A method for screening a test compound for potential efficacy in treatment of a disorder includes creating a first computer model representative of a volume of disease-afflicted neural tissue exposed to the test compound; and providing an initial excitation to the first computer model. Following a selected computation interval, a first outcome is determined. The first outcome indicates a response of the first computer model to the initial excitation and indicates whether the test compound has the potential to be effective in treating the disorder.

  一种筛选试验化合物对治疗疾病的潜在疗效的方法包括：创建一个代表暴露于试验化合物的受疾病影响的神经组织体积的第一计算机模型；以及向第一计算机模型提供初始激励。在选定的计算间隔之后，确定第一结果。第一结果表明第一计算机模型对初始激励的响应，并表明试验化合物是否有可能有效治疗疾病。
• NEURONAL AVALANCHE ASSAY
  申请人：The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services

  公开号：EP1921989A2

  公开（公告）日：2008-05-21